Gastroesophageal Cancers | Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 4

Featuring perspectives from Dr Samuel Klempner, including the following topics: Introduction (0:00) Case: A man in his mid 70s with gastric adenocarcinoma and oligometastatic disease to the liver (PD-L1 10%, HER2-positive) — Ranju Gupta, MD (2:47) Case: A man in his early 70s with locally advanced HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who undergoes chemoradiation therapy and surgery but develops progressive disease on adjuvant nivolumab and is now receiving CAPOX with trastuzumab (PD-L1 10%, microsatellite stable [MSS]) — Bruce Bank, MD (9:39) Treatment of Microsatellite Instability-High Disease (20:46) Case: A woman in her late 60s with GEJ adenocarcinoma metastatic to the liver (MSS, PD-L1 2%, HER2-negative) — Warren S Brenner, MD (36:32) Case: A man in his late 50s with GEJ adenocarcinoma who receives neoadjuvant fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT), is found to have 8/18 positive nodes at surgery, receives adjuvant FLOT and currently has no evidence of disease (PD-L1 Case: A man in his early 50s with esophageal adenocarcinoma with an FDG-avid mediastinal node who undergoes chemoradiation therapy and definitive radiation therapy to the node (MSS, PD-L1 0%, HER2-negative) — Jennifer L Dallas, MD (48:55) Case: A man in his mid 50s with a history of Barrett’s esophagus with T1bNXM0 adenocarcinoma with signet cell features who undergoes endoscopic resection and declines esophagectomy — Matthew R Strickland, MD (53:11) Case: A man in his early 60s with a 70-lb weight loss and locally advanced high-grade neuroendocrine carcinoma of the distal esophagus — Dr Gupta (56:58) CME information and select publications